Wir sind mit live! Mehr erfahren
RAPT-Symbol

RAPT Therapeutics
RAPT

Nicht mehr börsennotiert

RAPT wurde am 2. März 2026 von der Börse genommen.

Zurück zu den Rankings
 

Profil: RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Mitarbeiter: 60

Gesundheitswesen Biotechnologie

Nachrichten

Positiv
Neutral
Negativ
Stimmung 3 Monate
Positiv 0 %
Neutral 0 %
Negativ 0 %
Positiv
The Motley Fool
vor 7 Monaten
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges
Great Point Partners acquired 581,187 shares of RAPT Therapeutics in the fourth quarter. The quarter-end position value increased by $19.68 million due to the new position in RAPT Therapeutics.
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges
Neutral
Business Wire
vor 8 Monaten
RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of RAPT Therapeutics, Inc. (NasdaqGM: RAPT) to GSK plc (NYSE: GSK). Under the terms of the proposed transaction, shareholders of RAPT will receive $58.00 in cash for each share of RAPT that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or.
RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT
Neutral
GlobeNewsWire
vor 8 Monaten
Halper Sadeh LLC Encourages PEN and RAPT Shareholders to Contact the Firm to Discuss Their Rights
Shareholders should contact the firm as there may be limited time to enforce your rights Shareholders should contact the firm as there may be limited time to enforce your rights
Halper Sadeh LLC Encourages PEN and RAPT Shareholders to Contact the Firm to Discuss Their Rights
Neutral
Business Wire
vor 9 Monaten
RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of RAPT Therapeutics, Inc. (NasdaqGM: RAPT) to GSK plc (NYSE: GSK). Under the terms of the proposed transaction, shareholders of RAPT will receive $58.00 in cash for each share of RAPT that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or.
RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT
Positiv
Zacks Investment Research
vor 9 Monaten
GSK to Boost Respiratory & Immunology Pipeline With $2.2B RAPT Buyout
GSK agrees to buy RAPT Therapeutics for $2.2B, adding ozureprubart to its pipeline and strengthening its respiratory and immunology portfolio.
GSK to Boost Respiratory & Immunology Pipeline With $2.2B RAPT Buyout
Positiv
The Motley Fool
vor 9 Monaten
Why Rapt Therapeutics Stock Soared Today
GSK offered to buy Rapt Therapeutics for a sizable premium to its recent market value. Rapt's experimental antibody therapy could help millions of people who suffer from severe food allergies.
Why Rapt Therapeutics Stock Soared Today
Neutral
PRNewsWire
vor 9 Monaten
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of RAPT Therapeutics, Inc. (NASDAQ: RAPT)
NEW YORK, Jan. 20, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating RAPT Therapeutics, Inc. (NASDAQ: RAPT) related to its sale to GSK plc.
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of RAPT Therapeutics, Inc. (NASDAQ: RAPT)
Neutral
GlobeNewsWire
vor 9 Monaten
Forbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSK
NAARDEN, The Netherlands, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Forbion, a leading life sciences venture capital firm with deep roots in Europe, today announces that GSK (NYSE: GSK) has entered into a definitive agreement to acquire Forbion Growth Fund III portfolio company RAPT Therapeutics, Inc. (NASDAQ: RAPT) in a transaction valued at $2.2 billion.
Forbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSK
Neutral
PRNewsWire
vor 9 Monaten
Shareholder Alert: The Ademi Firm investigates whether RAPT Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders
MILWAUKEE, Jan. 20, 2026 /PRNewswire/ -- Ademi LLP is investigating RAPT (NASDAQ: RAPT) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with GSK plc. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.
Shareholder Alert: The Ademi Firm investigates whether RAPT Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders
Positiv
Investors Business Daily
vor 9 Monaten
GSK Digs In On Allergies With $2.2 Billion Rapt Therapeutics Buyout
GSK is buying Rapt Therapeutics for $2.2 billion, the companies said Tuesday. Rapt stock rocketed.
GSK Digs In On Allergies With $2.2 Billion Rapt Therapeutics Buyout
Nachrichtenrankings ansehen
Kursdiagramme mit Lightweight Charts™ umgesetzt